<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570504</url>
  </required_header>
  <id_info>
    <org_study_id>CTD1-2012</org_study_id>
    <secondary_id>2011-002784-24</secondary_id>
    <nct_id>NCT01570504</nct_id>
  </id_info>
  <brief_title>Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis</brief_title>
  <acronym>STRONGTREAT</acronym>
  <official_title>Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro per le Malattie Tropicali</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro per le Malattie Tropicali</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ivermectin is currently the best drug to cure strongyloidiasis, but the &quot;standard&quot; single
      dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal
      in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the
      parasite.

      Aim of this study is to define the most effective dose schedule of ivermectin to cure
      strongyloidiasis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clearance of strongyloides infection</measure>
    <time_frame>12 months</time_frame>
    <description>Clearance of infection is defined by: negative stool agar/charcoal culture/RT-PCR - direct examination of three faecal samples for S. stercoralis AND negative serology or decrease in titer below a defined cutoff</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality during the 12 months of follow-up.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with partial response to treatment at T 2</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with adverse reactions</measure>
    <time_frame>From Day 1st to Day 5th of treatment and from Day 15th to Day 19th (or 72 hours from treatment completion)</time_frame>
    <description>grade 1 to 5 as defined in detailed protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with increase in blood ALT over cutoff value</measure>
    <time_frame>Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with decrease in WBC count below cutoff value</measure>
    <time_frame>Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average difference in blood ALT and WBC count at day 17, compared with baseline</measure>
    <time_frame>Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average difference in blood eosinophil count at T2, compared with baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Strongyloidiasis</condition>
  <arm_group>
    <arm_group_label>ivermectin multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 dose ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 200 mcg/kg dose of ivermectin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>oral formulation</description>
    <arm_group_label>ivermectin multiple doses</arm_group_label>
    <arm_group_label>1 dose ivermectin</arm_group_label>
    <other_name>Stromectol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients older than 5 years and weighting &gt; 15 kg

          -  Current residence in non-endemic areas

          -  Either direct diagnosis of S. stercoralis infection AND positive serology at any titer
             OR positive serology at &quot;high&quot; titer, irrespective of results of direct tests

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Subjects suffering from CNS diseases

          -  Disseminated strongyloidiasis

          -  Immunocompromised patients.

          -  Lack of informed consent

          -  Previous treatment with ivermectin (in the last year)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zeno Bisoffi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Tropical Diseases, Negrar (Verona), Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro per le Malattie Tropicali, Ospedale Sacro Cuore</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Malattie Infettive e Tropicali</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UFDID, Azienda Ospedaliero-universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unit√† di Malattie Infettive, Anna Meyer Children's Universisty Hospital</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Medicina, Hospital de Poniente-El Ejido</name>
      <address>
        <city>El Ejido</city>
        <state>Almeria</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FCRB, Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unitat Medicina Tropical i Salut Internacional Drassanes</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital, Cambridge University Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLH</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Peru</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Strongyloidiasis</keyword>
  <keyword>Strongyloides stercoralis</keyword>
  <keyword>Ivermectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Strongyloidiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

